1246449-83-1

Upstream product

• 205640-31-9 2-((3-(((benzyloxy)carbonyl)amino)propanoyl)oxy)acetic acid 
• 75-75-2 methanesulfonic acid 
• 1246449-81-9 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((R)-12-((S)-((tert-butoxycarbonyl)amino)(phenyl)methyl)-3,7,10-trioxo-1-phenyl-2,8,11-trioxa-4-azatridecan-13-oyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate 

Relevant academic research and scientific papers

METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS

Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.

CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY

Methods and compositions relating to CDP-taxane conjugates are described herein.